Immuno-Oncology: The Next Steps in Care for Men Living with Prostate Cancer!

Oct 2, 2025

Doctors now use imaging and biomarkers to guide treatment, and then add immune-based drugs that help the body see and attack cancer. PSMA-directed radioligand therapy is one example that can delay or replace chemotherapy for some men, often with manageable side effects.

The fastest-moving area is T-cell engagers (TCEs) and bispecific antibodies. These drugs have two binding sites: one grabs a T cell and the other locks onto a tumor marker such as PSMA, B7-H3, or STEAP1. By bringing T cells right next to cancer cells, they trigger a focused immune attack. Newer designs last longer, need fewer infusions, and use “step-up” dosing to lower reactions like cytokine release syndrome.

 

Combinations may work even better.

TCEs and bispecifics are being paired with checkpoint inhibitors, radioligand therapy, PARP inhibitors, and drugs that re-program the tumor microenvironment. Biomarkers, including PSMA PET, tumor DNA, and RNA signals, help match the right patient to the right therapy and adjust care over time.

“Knowledge is your best defense against prostate cancer, and immuno-oncology may open new options for prostate cancer survivors.”

What you’ll learn:

  • How T-cell engagers and bispecifics work
  • Which biomarkers guide therapy choices
  • Clinical trials now recruiting at PHENTrials.com
  • What to ask your doctor about benefits, side effects, and visit schedule

Please join Drs. Nicholas Zorko and Keith Crawford for this opportunity to learn more about T-cell engagers and how bispecific antibodies could soon become core options alongside hormone therapy and radioligand therapy at PHEN’s next Managing Survivorship Meeting and Webinar on Wednesday, October 8th, 2025 at 6:00 PM ET.

 

Register now

 

Speakers

Keith Crawford, MD, PhD, Director of Clinical Trials and Patient Education, PHEN

Nicholas Zorko, MD, PhD, Assistant Professor of Medicine, University of Minnesota

 

Agenda:

  • Feature Presentation: Immuno-Oncology: The Next Steps in Care for Men Living with Prostate Cancer! with Dr. Nicholas Zorko
  • Clinical Trial Highlights: Dr. Keith Crawford will review an example of an immunotherapy clinical trial called XALute. (Click here to see if you qualify for this trial)
  • Survivor Man-to-Man: An informal discussion among prostate cancer survivors attending the in-person meeting at Dana-Farber Cancer Institute. 

Location:

Zoom or In-Person at Dana-Farber Cancer Institute, 450 Brookline Ave, (Jimmy Fund Way), 16th Floor, Rm 1620 (Smith Family) (Free parking and refreshments for in-person attendees)

 

View Posts by Category

Pin It on Pinterest